I. Alex Bowman - Concepedia

Author

I. Alex Bowman

The University of Texas Southwestern Medical Center ORCID

Also Known As

Alex Bowman, Bowman, I. Alex, I A Bowman, I Alex Bowman, I. Alex Bowman, I. Bowman, I.A. Bowman, Isaac A. Bowman, Isaac Alex Bowman, Isaac Bowman

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

The University of Texas Southwestern Medical Center Dana-Farber Cancer Institute Southwestern Medical Center Harold C. Simmons Comprehensive Cancer Center

About

I. Alex Bowman is an author at The University of Texas Southwestern Medical Center specializing in medicine, oncology, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	18	1.6K
2	Immunology	4	4	128
3	Health Sciences	2	2	23
4	Nephrology	2	2	131
5	Molecular Genetics	1	1	73

I. Alex Bowman

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, The Lancet Oncology First-line TherapyUrologyChemotherapy Versus ChemotherapyGenitourinary CancerMedicine	2021	627
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study Nieves Martínez Chanzá, Wanling Xie, Mehmet Asım Bilen, The Lancet Oncology UrologyGenitourinary CancerKidney ResearchMedicineRenal Pathology	2019	173
Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma Laure Hirsch, Nieves Martínez Chanzá, Subrina Farah, JAMA Oncology	2021	93
Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer Yuanyuan Zhang, Jonathan E. Schoenhals, Alana Christie, International Journal of Radiation OncologyBiologyPhysics UrologyDefer Systemic TherapyRadiation TherapyMedicineCancer Treatment	2019	92
Pancreatic tropism of metastatic renal cell carcinoma Nirmish Singla, Zhiqun Xie, Ze Zhang, JCI Insight UrologyPancreatic CancerGenitourinary CancerMedicineRcc Metastatic	2020	81
PD-L1 detection using 89Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response Joseph Vento, Aditi Mulgaonkar, Layton Woolford, Journal for ImmunoTherapy of Cancer	2019	75
ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events Terry L. Ng, Derek Smith, Rao Mushtaq, Journal of Thoracic Oncology Autoimmune DiseaseDisease MechanismGenetic DisorderGeneticsPathogenesis	2018	73
Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer Raquibul Hannan, Michael Christensen, Hans J. Hammers, European Urology Oncology Surgical OncologyUrologyPhase Ii TrialRadiation TherapyGenitourinary Cancer	2022	69
Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma Nirmish Singla, Roy Elias, Rashed Ghandour, Urologic Oncology Seminars and Original Investigations Surgical OncologyUrologyKidney TransplantGenitourinary CancerMedicine	2019	67
Current Approaches to the Treatment of Advanced or Metastatic Renal Cell Carcinoma Matthew E. Tenold, Praful Ravi, Monika Kumar, American Society of Clinical Oncology Educational Book Surgical OncologyUrologyGenitourinary CancerClear Cell TypeMedicine	2020	64

Page 1